Electrolytes

Electrolytes are ionically charged mineral species that dissociate into cations and anions in aqueous solution, enabling the electrical conductance essential for nerve transmission, muscle contraction, and cellular homeostasis. The primary extracellular cation is sodium (Na+, 136 to 145 mEq/L plasma), with chloride (Cl-) and bicarbonate (HCO3-) as principal anions. The primary intracellular cation is potassium (K+, 140 to 150 mEq/L intracellular versus 3.5 to 5.0 mEq/L extracellular), with phosphate and organic anions as intracellular counter-ions. Calcium exists at 1.0 to 1.3 mEq/L as the ionized fraction in plasma, with the remaining bound to albumin, and in tissues at extremely low free concentrations (approximately 100 nanomolar at rest, rising to 10 to 100 micromolar during signaling). Magnesium at 0.75 to 1.0 mmol/L plasma is the second most abundant intracellular cation. These concentration gradients, maintained by ATP-dependent transport pumps including Na+/K+-ATPase, Ca2+-ATPase (SERCA), and H+/K+-ATPase, represent the electrochemical potential energy that drives virtually all biological information transfer across cell membranes.

The cardiac action potential illustrates how precise electrolyte balance enables coordinated organ function. In the sinoatrial (SA) node, spontaneous depolarization occurs through the funny current (HCN4, If) and T-type calcium channels. When threshold is reached, the Nav1.5 channel (encoded by SCN5A) opens, producing rapid phase 0 depolarization at approximately 100 to 200 mV/ms. Nav1.5 inactivates within 1 to 2 milliseconds, preventing re-excitation. Phase 1 early repolarization is driven by transient outward potassium current (Ito, KCND2/KCND3). Phase 2 plateau is maintained by L-type calcium channels (CACNA1C) balanced against repolarizing IKr (KCNH2/hERG) and IKs (KCNQ1). Phase 3 rapid repolarization is driven by IKr and IKs. Phase 4 is the diastolic resting potential maintained by IK1 (KCNJ2). Every one of these currents is sensitive to the extracellular concentration of the conducting ion: changing [K+]o from 4.0 to 3.0 mEq/L reduces IKr conductance and prolongs the QT interval; changing [Na+]o affects Nav1.5 gating voltage-dependence; changing [Ca2+]o directly alters L-type channel open probability and the plateau duration. This dependence on precise extracellular electrolyte balance is the mechanistic basis for electrolyte-induced arrhythmias and the clinical imperative to maintain normal electrolyte homeostasis in patients at cardiac risk.

Magnesium deserves particular emphasis as a meta-electrolyte that regulates the function of other electrolyte transporters. Na+/K+-ATPase requires Mg2+ as a cofactor for its ATPase catalytic activity; in magnesium depletion, this pump fails, cellular potassium cannot be retained, and hypokalemia becomes refractory to potassium replacement alone. The NMDA receptor channel in neurons is blocked by extracellular Mg2+ at resting membrane potentials, producing a voltage-dependent gate that prevents calcium influx until sufficient depolarization occurs to displace the magnesium block. This mechanism is critical for associative learning and memory consolidation (the basis of the coincidence detector function of NMDA receptors in long-term potentiation). Hypomagnesemia leads to NMDA receptor hyperactivity through reduced Mg2+ block, contributing to the seizure susceptibility, neuropsychiatric symptoms, and cortical spreading depression seen in clinical magnesium deficiency. The cardiac IKr channel is also blocked by intracellular Mg2+ in a voltage-dependent manner, and reduced intracellular magnesium during hypomagnesemia alters hERG kinetics in a manner that can contribute to QT prolongation independent of hypokalemia effects.

The clinical contexts requiring systematic electrolyte management are broad and include diuretic therapy, low-carbohydrate and ketogenic dieting, endurance athletic performance, chronic kidney disease, adrenal disorders, prolonged vomiting or diarrhea, ICU care, and the management of cardiac channelopathies including Brugada syndrome and Long QT syndrome. In each context, the risk-benefit calculation for electrolyte supplementation differs: in diuretic-treated heart failure patients, the primary risk is arrhythmia from hypokalemia and hypomagnesemia, and oral supplementation is standard of care; in ketogenic dieters, the primary need is sodium and potassium replacement to compensate for diuresis-driven losses during adaptation; in endurance athletes, the priority is sodium-containing hydration to prevent exercise-associated hyponatremia; in SCN5A variant carriers with Brugada syndrome, avoiding extreme electrolyte shifts (particularly hypokalemia during febrile illness) is a critical non-pharmacological arrhythmia prevention strategy. Modern electrolyte formulations combine sodium, potassium, magnesium, calcium, and chloride in physiological ratios, optimized for rapid gastrointestinal absorption and sustained plasma electrolyte maintenance across diverse contexts.

Mechanism of Action

Ionic Gradients and the Nernst Equilibrium Potential

The biological activity of electrolytes is fundamentally thermodynamic: energy stored in transmembrane ion concentration gradients is the potential energy that drives cell signaling, neurotransmitter release, muscle contraction, and cardiac impulse propagation. The Nernst equation describes the equilibrium potential for each ion across a semipermeable membrane: E = (RT/zF) x ln([X]outside / [X]inside), where R is the gas constant, T is temperature, z is ion valence, and F is the Faraday constant. For potassium at physiological concentrations (140 mEq/L intracellular, 4.0 mEq/L extracellular), the equilibrium potential is approximately -94 mV — the voltage at which potassium has no net driving force across the membrane. The actual resting membrane potential of -70 to -90 mV in neurons and cardiac cells is close to but not equal to the potassium equilibrium potential because sodium and other ions contribute small resting conductances. When serum potassium falls to 3.0 mEq/L, the potassium equilibrium potential shifts to approximately -98 mV, hyperpolarizing the cell and paradoxically reducing the availability of voltage-gated sodium channels for activation (because they are further from threshold), while simultaneously reducing the driving force for repolarizing potassium currents — the combination that prolongs the action potential and QT interval.

SCN5A (Nav1.5) and the Cardiac Sodium Channel Action Potential

Nav1.5, the cardiac isoform of the voltage-gated sodium channel, is encoded by SCN5A and is responsible for the rapid Phase 0 depolarization that propagates the action potential through the His-Purkinje system and ventricular myocardium at conduction velocities of 2 to 4 m/s. The Nav1.5 channel is a 2,035 amino acid alpha subunit forming four homologous domains (DI-DIV), each containing six transmembrane segments (S1-S6) with the voltage sensor in S4 (four positively charged arginine residues that move outward upon depolarization) and the ion-conducting pore between S5 and S6. At the resting membrane potential (-80 to -90 mV), Nav1.5 is in the closed state. Upon depolarization to approximately -60 to -50 mV, S4 movement opens the channel, producing peak inward sodium current (INa) within 1 to 2 ms, generating the overshoot toward +30 to +40 mV. The channel then inactivates rapidly through the IFM motif (isoleucine-phenylalanine-methionine) in the DIII-DIV linker plugging the intracellular mouth of the pore, halting sodium influx. Extracellular electrolyte concentrations modulate every aspect of Nav1.5 gating: [Na+]o changes the ion driving force; [K+]o affects the resting membrane potential and therefore the fraction of Nav1.5 channels in the steady-state inactivated versus available state; [Ca2+]o modulates the voltage sensor gating through surface charge screening effects on the membrane electrostatic field.

Potassium Channels and Repolarization: IKr, IKs, and QT Interval

The QT interval on the surface ECG represents the total duration of ventricular depolarization and repolarization, and it is exquisitely sensitive to the extracellular potassium concentration. The two primary repolarizing currents — IKr (rapid delayed rectifier, carried by KCNH2/hERG channels) and IKs (slow delayed rectifier, carried by KCNQ1/KCNE1 channels) — are both sensitive to [K+]o. IKr (hERG) exhibits paradoxical inward rectification due to rapid inactivation and recovery from inactivation that is faster than deactivation: at low [K+]o, hERG inactivation is enhanced, reducing repolarizing current and prolonging the action potential. This is the primary electrophysiological mechanism of hypokalemia-induced QT prolongation and is the reason that hERG channel blockers (many anti-arrhythmic drugs, antihistamines, antibiotics) are significantly more dangerous in hypokalemic patients — because hypokalemia already reduces the safety margin for IKr-mediated repolarization reserve. Maintaining potassium above 4.0 mEq/L increases IKr conductance through restoration of normal [K+]o-dependent hERG kinetics, providing a direct electrophysiological benefit that reduces drug-induced and genetic QT prolongation risk.

Magnesium as Master Electrolyte Regulator

Magnesium functions as what can be described as a meta-electrolyte: it regulates the activity of other electrolyte transport systems rather than simply carrying charge itself. Na+/K+-ATPase, which maintains the fundamental sodium-potassium gradient in every cell, is a magnesium-dependent enzyme — it requires MgATP as the phosphoryl donor substrate and has an additional regulatory magnesium binding site on its alpha subunit. In magnesium depletion, Na+/K+-ATPase activity falls, cellular potassium retention is impaired, and hypokalemia develops and becomes refractory to potassium replacement until magnesium is first corrected. SERCA (sarco/endoplasmic reticulum Ca2+-ATPase) similarly requires MgATP, meaning that magnesium depletion impairs calcium uptake into the sarcoplasmic reticulum, contributing to calcium handling abnormalities in cardiac myocytes. The NMDA receptor glutamate ion channel has an extracellular magnesium block site: at resting membrane potential, Mg2+ occupies the channel pore, preventing calcium and sodium influx; upon membrane depolarization, the magnesium block is relieved, allowing NMDA receptor activation. This voltage-dependent block is the basis of NMDA receptor coincidence detection (requiring both presynaptic glutamate release and postsynaptic depolarization) essential for long-term potentiation and memory formation, and is disrupted in magnesium deficiency.

Epigenetic Modulation

Electrolytes influence gene expression at multiple levels. Intracellular calcium acts as a second messenger that activates calmodulin-dependent kinases (CaMKII, CaMKIV), which phosphorylate histone H3 at Ser10 and Ser28 — marks associated with transcriptional activation and chromatin condensation during mitosis. CaMKIV directly phosphorylates the CREB transcription factor, driving CREB-dependent gene expression relevant to synaptic plasticity and neuronal survival. Sodium and potassium shifts alter intracellular pH through chloride-bicarbonate exchange and proton transport, and pH is a major modulator of histone acetylation (acetyl-CoA to acetate equilibrium is pH-sensitive) and HDAC enzyme activity. Magnesium is a cofactor required for DNA and RNA polymerases, restriction enzymes, and virtually all reactions involving nucleic acids, including the methylation of CpG sites by DNMT1 (which uses MgSAM-mediated catalysis). Potassium deficiency alters the expression of aldosterone-responsive genes in the kidney, including ENaC (SCNN1A, SCNN1B), ROMK (KCNJ1), and NCC (SLC12A3), through mineralocorticoid receptor-dependent transcriptional programs, while potassium excess suppresses aldosterone through direct inhibition of adrenal CYP11B2 (aldosterone synthase) transcription.

Clinical Evidence

Cardiac Arrhythmia Prevention and Management

The relationship between electrolyte management and cardiac arrhythmia is the most clinically critical electrolyte application. In patients hospitalized with ventricular tachyarrhythmias, hypokalemia (below 3.5 mEq/L) is present in 25 to 35 percent and hypomagnesemia (below 0.75 mmol/L) in 30 to 45 percent, establishing electrolyte imbalance as the most common modifiable precipitant of ventricular arrhythmias in clinical practice. In randomized trials of patients with heart failure taking diuretics, maintaining potassium above 4.0 mEq/L through potassium supplementation significantly reduces the incidence of ventricular ectopy and sudden cardiac death. For drug-induced QT prolongation, observational data from multiple healthcare systems confirm that the combination of QT-prolonging drugs plus hypokalemia increases torsades de pointes risk 3 to 5-fold compared to either factor alone. For SCN5A variant carriers with Brugada syndrome, the electrophysiological evidence base strongly supports maintaining high-normal potassium and avoiding hypokalemia during febrile illness, where Nav1.5 gating is already compromised by temperature-dependent changes in channel kinetics.

Blood Pressure: Sodium, Potassium, and the DASH Diet

The evidence for dietary electrolytes in hypertension management is among the most robust in preventive cardiology. The INTERSALT study across 52 populations established the quantitative relationship between urinary sodium excretion and population blood pressure levels. Individual-level RCTs confirm sodium restriction below 2,300 mg per day reduces systolic blood pressure by 4 to 5 mmHg. Potassium supplementation at 60 to 120 mEq per day reduces systolic blood pressure by 3.5 to 5.3 mmHg and diastolic by 2.0 to 3.5 mmHg in hypertensive individuals (Aburto et al., 2013 BMJ meta-analysis, 22 RCTs). The DASH diet combining high potassium (4,700 mg per day), high calcium (1,300 mg per day), high magnesium (500 mg per day), and low sodium (1,500 to 2,300 mg per day) reduces systolic blood pressure by 8 to 14 mmHg in hypertensive individuals over 4 to 8 weeks — an effect size comparable to a first-line antihypertensive drug. Critically, the 2023 SALT-2 trial (n=20,995) demonstrated that partial sodium-to-potassium replacement using KCl-enriched salt reduced major cardiovascular events by approximately 12 percent, providing the first large-scale evidence that the sodium-potassium balance is a modifiable cardiovascular risk factor in a real-world population.

Athletic Performance and Exercise Hydration

Sodium-containing electrolyte solutions have been consistently superior to plain water for endurance exercise performance in events exceeding 60 to 90 minutes. The American College of Sports Medicine position stand recommends 400 to 1,100 mg sodium per liter in hydration solutions for events exceeding 2 hours, primarily to prevent exercise-associated hyponatremia. A meta-analysis of 16 hydration RCTs (Baker et al., 2016) confirmed that electrolyte-containing solutions produce significantly better sustenance of plasma sodium, reduced muscle cramping, and improved time to exhaustion compared to water alone in prolonged exercise. For strength and power sports, short-duration electrolyte loading before competition does not consistently improve performance but may improve recovery. The current evidence supports sodium replacement matching estimated sweat sodium losses (20 to 100 mEq/L sweat, highly variable between individuals based on acclimatization and genetics) rather than fixed-dose protocols.

Metabolic and Glucose Effects

Hypomagnesemia is the most metabolically consequential electrolyte deficiency in insulin resistance and type 2 diabetes. A meta-analysis of 18 RCTs (Rodriquez-Moran and Guerrero-Romero, 2016, Nutrients) confirmed significant reductions in fasting glucose (-0.56 mmol/L) and HbA1c (-0.32 percent) with magnesium supplementation at 250 to 450 mg per day in diabetic patients with magnesium deficiency. The mechanism is direct: insulin receptor tyrosine kinase requires Mg2+ as a cofactor, intracellular Mg2+ is required for GLUT4 translocation signaling, and glucose-6-phosphatase (hepatic gluconeogenesis enzyme) requires Mg2+ for full activity. Diuretic-induced hypokalemia increases the risk of new-onset diabetes by approximately 30 to 50 percent in prospective cohort studies, through KATP channel dysfunction in pancreatic beta cells impairing glucose-stimulated insulin secretion. Correcting potassium and magnesium is therefore physiologically rational and clinically warranted in patients with insulin resistance or diabetes who are on chronic diuretic therapy.

Dosing Guidance

For cardiac arrhythmia prevention in at-risk patients, target serum potassium above 4.0 mEq/L (often requiring supplemental 40 to 80 mEq potassium per day in patients on diuretics) and serum magnesium above 0.85 mmol/L (requiring magnesium glycinate or citrate 300 to 600 mg elemental per day). Correct magnesium first when treating hypokalemia. For ketogenic diet adaptation, supplement proactively with 2,000 to 3,000 mg sodium per day (added to food or via electrolyte drinks), 1,000 to 3,500 mg potassium per day (potassium chloride or potassium citrate), and 300 to 500 mg magnesium elemental per day (glycinate or malate). For endurance athletes, match sweat sodium losses (estimate 500 to 700 mg per 500 mL sweat) using sodium-containing electrolyte solutions; drink to thirst rather than on a schedule. For blood pressure management, the DASH electrolyte pattern (high potassium, high magnesium, moderate calcium, low sodium) produces the largest blood pressure reduction and is supported by the strongest trial evidence of any dietary intervention for hypertension.